RVMD
VENTE TOTALE: 80 000 titres (~16 578 640,00 $ US)
- Insiders
- GOLDSMITH MARK A
- Total bought
- —
- Total sold
- $16,578,640
- Last activity
- 2026-08-21
- Last synced
-
2026-08-27 10:00:12
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bullish signal Scored 2026-08-27
RVMD carries a high-impact catalyst — FDA approval of daraxonrasib for metastatic pancreatic cancer — that drives strong near-term upside potential, reflected in its elevated catalyst score of 85.
The first sentence of the analysis written for RVMD on 2026-08-27 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 100.0% | 100.0% | 100.0% | |
| Ebit Margin | 0.0% | 0.0% | -3796.1% | -704.1% | -636.5% | |
| Ebitda Margin | 0.0% | 0.0% | -3715.7% | -676.8% | -611.6% | |
| Operating Profit Margin | 0.0% | 0.0% | -4207.1% | -730.0% | -639.7% | |
| Pretax Profit Margin | 0.0% | 0.0% | -3798.7% | -704.1% | -636.6% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | -3768.3% | -703.0% | -636.6% | |
| Net Profit Margin | 0.0% | 0.0% | -3768.3% | -703.0% | -636.6% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | -3768.3% | -703.0% | -636.6% | |
| Current Ratio | 7.145 | 14.200 | 13.064 | 10.651 | 9.773 | |
| Quick Ratio | 7.145 | 14.200 | 13.064 | 10.651 | 9.773 | |
| Solvency Ratio | -1.541 | -2.007 | -1.813 | -1.886 | -1.327 | |
| Cash Ratio | 1.321 | 3.313 | 4.839 | 2.604 | 1.798 | |
| Price To Earnings Ratio | -13.387 | -12.218 | -7.430 | -7.734 | -10.190 | |
| Price To Earnings Growth Ratio | -0.202 | 1.684 | -0.293 | -0.313 | -0.194 | |
| Forward Price To Earnings Growth Ratio | -0.202 | 1.684 | -0.293 | -0.313 | -0.194 | |
| Price To Earnings Diluted Ratio | -13.387 | -12.218 | -7.430 | -7.734 | -10.190 | |
| Price To Earnings Diluted Growth Ratio | -0.202 | 1.684 | -0.293 | -0.313 | -0.194 | |
| Price To Book Ratio | 9.283 | 3.239 | 1.777 | 2.803 | 3.041 | |
| Price To Sales Ratio | 0.000 | 0.000 | 280.236 | 54.283 | 62.352 | |
| Price To Free Cash Flow Ratio | -16.574 | -12.923 | -9.057 | -8.165 | -11.922 | |
| Price To Operating Cash Flow Ratio | -16.869 | -13.162 | -9.257 | -8.558 | -12.451 | |
| Debt To Assets Ratio | 0.067 | 0.053 | 0.043 | 0.079 | 0.090 | |
| Debt To Equity Ratio | 0.097 | 0.060 | 0.048 | 0.094 | 0.111 | |
| Debt To Capital Ratio | 0.089 | 0.057 | 0.046 | 0.086 | 0.100 | |
| Long Term Debt To Capital Ratio | 0.080 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.443 | 1.129 | 1.129 | 1.185 | 1.225 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.010 | 0.063 | 0.063 | |
| Operating Cash Flow Ratio | -3.091 | -3.401 | -2.437 | -3.620 | -2.439 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | -30.274 | -6.343 | -5.008 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.018 | 1.018 | 1.022 | 1.048 | 1.044 | |
| Debt Service Coverage Ratio | -45.005 | 0.000 | -1,408.432 | 0.000 | -14,978.917 | |
| Interest Coverage Ratio | -48.796 | 0.000 | -1,607.871 | 0.000 | -15,667.333 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -5.657 | -4.104 | -3.986 | -3.495 | -2.209 | |
| Capital Expenditure Coverage Ratio | -56.144 | -54.078 | -45.358 | -20.747 | -22.546 | |
| Dividend Paid And Capex Coverage Ratio | -56.144 | -54.078 | -45.358 | -20.747 | -22.546 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -13.680 | -11.765 | -6.128 | -7.614 | -9.962 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | ▼-60.0% |
| Ebit Margin | 0.0% | 0.0% | ▲1027.4% |
| Ebitda Margin | 0.0% | 0.0% | ▲1000.8% |
| Operating Profit Margin | 0.0% | 0.0% | ▲1115.4% |
| Pretax Profit Margin | 0.0% | 0.0% | ▲1027.9% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | ▲1021.6% |
| Net Profit Margin | 0.0% | 0.0% | ▲1021.6% |
| Bottom Line Profit Margin | 0.0% | 0.0% | ▲1021.6% |
| Current Ratio | 7.145 | ▼-7.056 | ▼-3.822 |
| Quick Ratio | 7.145 | ▼-7.056 | ▼-3.822 |
| Solvency Ratio | -1.541 | ▲0.466 | ▲0.174 |
| Cash Ratio | 1.321 | ▼-1.992 | ▼-1.454 |
| Price To Earnings Ratio | -13.387 | ▼-1.169 | ▼-3.195 |
| Price To Earnings Growth Ratio | -0.202 | ▼-1.887 | ▼-0.339 |
| Forward Price To Earnings Growth Ratio | -0.202 | ▼-1.887 | ▼-0.339 |
| Price To Earnings Diluted Ratio | -13.387 | ▼-1.169 | ▼-3.195 |
| Price To Earnings Diluted Growth Ratio | -0.202 | ▼-1.887 | ▼-0.339 |
| Price To Book Ratio | 9.283 | ▲6.044 | ▲5.255 |
| Price To Sales Ratio | 0.000 | 0.000 | ▼-79.374 |
| Price To Free Cash Flow Ratio | -16.574 | ▼-3.651 | ▼-4.846 |
| Price To Operating Cash Flow Ratio | -16.869 | ▼-3.707 | ▼-4.809 |
| Debt To Assets Ratio | 0.067 | ▲0.014 | ▲0.001 |
| Debt To Equity Ratio | 0.097 | ▲0.037 | ▲0.015 |
| Debt To Capital Ratio | 0.089 | ▲0.032 | ▲0.013 |
| Long Term Debt To Capital Ratio | 0.080 | ▲0.080 | ▲0.064 |
| Financial Leverage Ratio | 1.443 | ▲0.314 | ▲0.221 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | ▼-0.027 |
| Operating Cash Flow Ratio | -3.091 | ▲0.310 | ▼-0.093 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | ▲8.325 |
| Free Cash Flow Operating Cash Flow Ratio | 1.018 | ▼-0.001 | ▼-0.012 |
| Debt Service Coverage Ratio | -45.005 | ▼-45.005 | ▲3241.466 |
| Interest Coverage Ratio | -48.796 | ▼-48.796 | ▲3416.004 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -5.657 | ▼-1.553 | ▼-1.767 |
| Capital Expenditure Coverage Ratio | -56.144 | ▼-2.066 | ▼-16.369 |
| Dividend Paid And Capex Coverage Ratio | -56.144 | ▼-2.066 | ▼-16.369 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -13.681 | ▼-1.916 | ▼-3.851 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $15.14B | $7.34B | $3.25B | $1.92B | $1.83B | |
| Enterprise value | $14.92B | $6.93B | $2.64B | $1.82B | $1.79B | |
| EV / Sales | 0.00x | 0.00x | 227.72x | 51.53x | 60.93x | |
| EV / Op. cash flow | -16.62x | -12.43x | -7.52x | -8.12x | -12.17x | |
| EV / Free cash flow | -16.33x | -12.21x | -7.36x | -7.75x | -11.65x | |
| EV / EBITDA | -13.68x | -11.77x | -6.13x | -7.61x | -9.96x | |
| Net debt / EBITDA | 0.21x | 0.69x | 1.41x | 0.41x | 0.23x | |
| Current ratio | 7.14x | 14.20x | 13.06x | 10.65x | 9.77x | |
| Income quality | 0.79x | 0.93x | 0.80x | 0.90x | 0.79x | |
| Graham net-net | $7 | $12 | $14 | $6 | $6 | |
| Tax burden | 100.0% | 99.9% | 99.2% | 99.8% | 100.0% | |
| Interest burden | 102.2% | 100.0% | 100.1% | 100.0% | 100.0% | |
| Working capital | $1.78B | $2.16B | $1.74B | $598.2M | $529.4M | |
| Invested capital | $2.02B | $2.38B | $1.91B | $745.4M | $675.1M | |
| Return on assets | -48.0% | -23.5% | -21.2% | -30.6% | -25.4% | |
| Operating ROA | -48.1% | -29.8% | -33.9% | -33.3% | -28.8% | |
| Return on tangible assets | -49.5% | -24.1% | -21.9% | -33.7% | -28.2% | |
| Return on equity | -69.3% | -26.5% | -23.9% | -36.3% | -31.0% | |
| Return on invested capital | -56.8% | -28.6% | -25.1% | -34.1% | -27.5% | |
| Return on capital employed | -57.3% | -28.8% | -25.4% | -34.4% | -27.7% | |
| Earnings yield | -7.5% | -8.2% | -13.4% | -12.9% | -10.2% | |
| Free cash flow yield | -6.0% | -7.7% | -11.0% | -12.2% | -8.4% | |
| Capex / Op. cash flow | -1.8% | -1.8% | -2.2% | -4.8% | -4.4% | |
| Capex / Depreciation | -59.3% | 87.2% | 83.0% | 112.0% | 89.0% | |
| Capex / Sales | 0.0% | 0.0% | 66.7% | 30.6% | 22.2% | |
| SG&A / Sales | 0.0% | 0.0% | 653.0% | 114.7% | 103.6% | |
| R&D / Sales | 0.0% | 0.0% | 3654.1% | 715.3% | 636.1% | |
| Stock comp / Sales | 0.0% | 0.0% | 533.4% | 88.2% | 70.5% | |
| Intangibles / Total assets | 3.0% | 2.8% | 3.5% | 9.0% | 10.1% | |
| Days sales outstanding | 0d | 0d | 40d | 48d | 74d | |
| Days payables outstanding | 1424d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 40d | 48d | 74d | |
| Cash conversion cycle | -1424d | 0d | 40d | 48d | 74d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+106.4%EV / Sales n/aEV / EBITDA ▼-16.3%EV / Op. cash flow ▼-4.187Earnings yield ▲+0.007
Profitability
Return on equity ▼-0.429Return on assets ▼-0.246Return on invested capital ▼-0.282Return on capital employed ▼-0.285Operating ROA ▼-0.183Income quality ▼-0.135Tax burden ▲+0.001
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-7.055Net debt / EBITDA ▼-0.485Working capital ▼-379105000.000Invested capital ▼-356520000.000Intangibles / Total assets ▲+0.002
Change over 5 years
Valuation
Market cap ▲+726.4%EV / Sales ▼-100.0%EV / EBITDA ▼-37.3%EV / Op. cash flow ▼-4.452Earnings yield ▲+0.027
Profitability
Return on equity ▼-0.383Return on assets ▼-0.227Return on invested capital ▼-0.293Return on capital employed ▼-0.295Operating ROA ▼-0.193Income quality ▲+0.007Tax burden 0.000
Efficiency
Days sales outstanding ▼-73.633Days payables outstanding n/aOperating cycle ▼-73.633Cash conversion cycle ▼-1498.011Capex / Sales ▼-0.222R&D / Sales ▼-6.361
Balance-sheet strength
Current ratio ▼-2.628Net debt / EBITDA ▼-0.027Working capital ▲+1255190000.000Invested capital ▲+1345156000.000Intangibles / Total assets ▼-0.071
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-26 U.S. FDA Approves Revolution Medicines'' RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer This release contains multimedia assets available for download here
- 2026-08-26 Revolution Medicines Wins FDA Approval for Pancreatic Cancer Pill. What It Means for the Stock. Daraxonrasib, the pill touted by a former member of Congress and cancer patient as a ‘miracle drug,'' has been granted approval in patients with pancreatic adenocarcinoma.
- 2026-08-26 The FDA approved a new drug from Revolution Medicines that promises to transform treatment of pancreatic cancers that kill many patients within a year of diagnosis The FDA approved a therapy from Revolution Medicines that slows a cancer that kills 7 of out 8 patients within five years.
- 2026-08-26 Revolution Medicines gets FDA nod for targeted pancreatic cancer drug The U.S. Food and Drug Administration on Wednesday approved Revolution Medicines'' targeted drug for adults with metastatic pancreatic cancer who have received prior treatment or cannot receive combination chemotherapy.
- 2026-08-25 Billionaire Stanley Druckenmiller Continues to Load Up on Revolution Medicines. Does He Know Something Wall Street Doesn''t? Druckenmiller added roughly 26.5% to his position in Revolution Medicines in Q2. Analysts like the biotech stock, but the consensus price target reflects only modest upside potential.
- 2026-08-24 GLP-1 Drugs Are Huge. These 2 Stocks Are Tapping Into an Even Bigger Opportunity Could these 2 stocks outperform most GLP-1-focused companies over the medium term?
- 2026-08-12 Why Revolution Medicines May Be Big Pharma''s Next Takeover Target Revolution Medicines (NASDAQ:RVMD | RVMD Price Prediction) closed at $205.55 on August 11, 2026, giving the pre-commercial oncology platform a market cap of $44.1 billion.
- 2026-08-11 Revolution Medicines (NASDAQ:RVMD) Sets New 12-Month High – Should You Buy? Revolution Medicines, Inc. (NASDAQ: RVMD - Get Free Report) hit a new 52-week high during mid-day trading on Tuesday. The stock traded as high as $208.76 and last traded at $206.97, with a volume of 2100357 shares trading hands. The stock had previously closed at $205.15. Analyst Upgrades and Downgrades Several equities research analysts have
- 2026-08-10 BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration SAN CARLOS, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution.
- 2026-08-07 High Risk, High Reward: Inside The Revolution Medicines Bull Case Revolution Medicines is evolving from a clinical-stage biotech to a near-term commercial oncology player, anchored by its RAS(ON) inhibitor platform. RVMD''s robust $3.9 billion cash position and additional committed capital support aggressive pipeline expansion and commercial launch readiness, reducing near-term dilution risk. Daraxonrasib''s potential FDA approval and commercial launch in pancreatic cancer could fundamentally transform RVMD''s financial profile and validate its broader RAS-targeted strategy.